New Evidence Supports Chromogenic Assays After Hemophilia A Gene Therapy – JTH
Journal of Thrombosis and Haemostasis (JTH) shared on LinkedIn about a recent article by Flora Peyvandi et al, adding:
”Correlation between Factor VIII chromogenic activity and antigen levels in patients treated with adeno-associated virus 5-mediated gene therapy for hemophilia A
In four patients with severe hemophilia A, FVIII antigen levels closely matched chromogenic assay results after gene therapy, supporting it as the preferred monitoring method.”
Title: Correlation between Factor VIII chromogenic activity and antigen levels in patients treated with adeno-associated virus 5-mediated gene therapy for hemophilia A
Authors: Flora Peyvandi, Isabella Garagiola, Novembrino Cristina, Lucia Schiavone, Massimo Boscolo-Anzoletti, Alessandro Ciavarella, Vincenzo La Mura
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 14, 2026, 13:04Mohammed M. Aboudeif: Cerebral Venous Thrombosis – Think Early, Treat Decisively
-
Aug 14, 2026, 12:49Ahmed Hawash: The Hawash Method for Managing Extreme ICU Complexity
-
Aug 14, 2026, 12:42Why Unfractionated Heparin Still Matters in Modern Anticoagulation – Thrombosis Canada
-
Aug 14, 2026, 11:40Liz Devlin: When HHT Affects More Than What We Can See
-
Aug 14, 2026, 11:29Archil Jaliashvili: Can Italy Reduce Its Dependence on Imported Plasma
-
Aug 14, 2026, 11:21Osama Alabdi: Never Ignore a Weak Reaction in the Blood Bank
-
Aug 14, 2026, 11:14Yohan Santin: How Lysosomal Dysfunction Drives Cardiac Aging
-
Aug 14, 2026, 11:06Nicolas Schommer: When Neutrophils Turn Metabolic Stress Into Organ Injury
-
Aug 14, 2026, 10:49Pablo Corral: Can One Infusion Lower LDL for Years